The FDA approved a groundbreaking new treatment, called Amtagvi, for advanced melanoma. It works by multiplying the body's immune cells inside the tumor, amplifying their ability to fight back. Known as TIL therapy, it's approved as a secondary treatment for patients who don't improve from primary options, including surgery. Amtagvi, from Iovance Biotherapeutics, is going to Phase 3 trials and may someday be used to fight other cancers like lung cancer, colon cancer, and more. The therapy is expected to cost over $500,000 per patient.
- Категория
- Онкодерматология
Комментариев нет.